PANACEABIO

Panacea Biotec Share Price

₹324.00 -17.45 (-5.11%)

22 Feb, 2025 21:23

SIP TrendupStart SIP in PANACEABIO

Start SIP

Performance

  • Low
  • ₹321
  • High
  • ₹349
  • 52 Week Low
  • ₹112
  • 52 Week High
  • ₹491
  • Open Price₹339
  • Previous Close₹341
  • Volume136,984

Investment Returns

  • Over 1 Month -23.52%
  • Over 3 Month -21.74%
  • Over 6 Month + 55.37%
  • Over 1 Year + 104.09%
SIP Lightning

Smart Investing Starts Here Start SIP with Panacea Biotec for Steady Growth!

Invest Now

Panacea Biotec Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -250.9
  • PEG Ratio
  • -7.1
  • Market Cap Cr
  • 1,985
  • P/B Ratio
  • 2.4
  • Average True Range
  • 28.18
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • -15.57
  • RSI
  • 39.2
  • MFI
  • 55.82

Panacea Biotec Financials

Panacea Biotec Technicals

EMA & SMA

Current Price
₹324.00
-17.45 (-5.11%)
pointer
  • stock-down_img
  • Bullish Moving Average 2
  • stock-up_img
  • Bearish Moving Average 14
  • 20 Day
  • ₹357.53
  • 50 Day
  • ₹377.73
  • 100 Day
  • ₹362.18
  • 200 Day
  • ₹310.17

Resistance and Support

331.25 Pivot Speed
  • R3 370.60
  • R2 359.90
  • R1 341.95
  • S1 313.30
  • S2 302.60
  • S3 284.65

What's your outlook on Panacea Biotec?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Panacea Biotec is a biotechnology company specializing in research, development, and manufacturing of vaccines, pharmaceuticals, and biosimilars. It operates state-of-the-art facilities in India, serving global markets across North America, Europe, and emerging economies.

Panacea Biotec (Nse) has an operating revenue of Rs. 563.02 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 0% needs improvement, ROE of -0% is poor and needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 21% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 64 which is a FAIR score but needs to improve its earnings, a RS Rating of 93 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 47 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Panacea Biotec Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-14 Quarterly Results
2024-11-13 Quarterly Results
2024-08-14 Quarterly Results
2024-05-30 Audited Results
2024-02-13 Quarterly Results

Panacea Biotec F&O

Panacea Biotec Shareholding Pattern

72.49%
0%
0.38%
18.98%
8.15%

About Panacea Biotec

  • NSE Symbol
  • PANACEABIO
  • BSE Symbol
  • 531349
  • Chairman & Managing Director
  • Dr. Rajesh Jain
  • ISIN
  • INE922B01023

Similar Stocks to Panacea Biotec

Panacea Biotec FAQs

Panacea Biotec share price is ₹324 As on 22 February, 2025 | 21:09

The Market Cap of Panacea Biotec is ₹1984.5 Cr As on 22 February, 2025 | 21:09

The P/E ratio of Panacea Biotec is -250.9 As on 22 February, 2025 | 21:09

The PB ratio of Panacea Biotec is 2.4 As on 22 February, 2025 | 21:09

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23